Curanex Expands Drug Pipeline to Include Cancer Cachexia

New focus represents multi-billion-dollar market opportunity and evolution of company's therapeutics development

Apr. 2, 2026 at 1:37pm

Got story updates? Submit your updates here. ›

Curanex Pharmaceuticals, a development-stage therapeutics company, announced it is expanding its drug development pipeline to include cancer cachexia, a serious cancer-associated wasting syndrome. The company believes this area represents a significant unmet need and commercial opportunity, as there are currently no approved therapies for cancer cachexia in the U.S. Curanex's lead program, Phyto-N, is advancing through preclinical studies for ulcerative colitis, while the company also evaluates additional development opportunities in diseases involving inflammation, metabolic dysfunction and physical decline.

Why it matters

Cancer cachexia is a major complication in oncology, affecting up to 80% of advanced cancer patients and severely reducing their strength, quality of life and ability to tolerate therapy. Despite its significant clinical burden, there are no approved treatments, representing a major unmet need. Curanex's expansion into this area aligns with its broader focus on serious diseases involving inflammation, metabolic issues and physical decline.

The details

Curanex is expanding its pipeline beyond its six core indications - ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD and gout - to now include cancer cachexia. The global cancer cachexia market was estimated at $2.54 billion in 2024 and is projected to grow to $3.90 billion by 2033. As Curanex advances its lead Phyto-N program for ulcerative colitis, it is also evaluating additional development opportunities in diseases involving inflammation, metabolic dysfunction and physical decline.

  • Curanex announced the pipeline expansion on April 2, 2026.
  • The global cancer cachexia market was approximately $2.54 billion in 2024 and is projected to grow to $3.90 billion by 2033.

The players

Curanex Pharmaceuticals, Inc.

A development-stage therapeutics company headquartered in Jericho, New York, that is advancing drug development programs for serious diseases with significant unmet medical need.

Jun Liu

The Chief Executive Officer of Curanex Pharmaceuticals.

National Cancer Institute

The organization that estimates cancer cachexia can occur in up to 80% of patients with advanced cancer.

Grand View Research

The research firm that provided the market size estimates for the global cancer cachexia market.

Got photos? Submit your photos here. ›

What they’re saying

“Cancer cachexia remains one of the largest unmet needs in supportive oncology, with serious consequences for patients and very limited treatment options. We believe this area represents a meaningful opportunity for focused drug development and an important step in the evolution of Curanex into a broader therapeutics development company.”

— Jun Liu, Chief Executive Officer, Curanex Pharmaceuticals

What’s next

Curanex plans to advance its lead program, Phyto-N, through preclinical studies in preparation for a planned Investigational New Drug (IND) submission for ulcerative colitis. The company will also continue evaluating additional development opportunities in serious diseases involving inflammation, metabolic dysfunction and physical decline, including its new focus on cancer cachexia.

The takeaway

Curanex's expansion into cancer cachexia treatment represents a significant opportunity to address a major unmet need in oncology, as the syndrome can severely impact patients' quality of life and ability to tolerate cancer therapies. By broadening its pipeline beyond its initial core indications, Curanex is positioning itself as an emerging therapeutics company focused on serious diseases with high unmet medical needs.